Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10690328 | 0.82 | LMNA (0.80) | LMNAALDH1A1HRH3SIGMAR1HRH4 | |
| SCHEMBL2479586 | 0.81 | KMT2A (0.69) | LMNAALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL28089650 | 0.81 | ALDH1A1 (0.58) | LMNAALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL54966 | 0.78 | ALDH1A1 (0.96) | LMNAALDH1A1HRH3HRH4KDM4E | |
| SCHEMBL3153045 | 0.78 | ALDH1A1 (0.88) | LMNAALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL22361100 | 0.78 | MEN1 (0.42) | LMNAALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL2518711 | 0.77 | HDAC1 (0.49) | LMNAALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL55983 | 0.77 | LMNA (1.00) | LMNAALDH1A1KMT2AHRH3KDM4E | |
| SCHEMBL62541 | 0.76 | ALDH1A1 (1.00) | LMNAALDH1A1HRH3HRH4KDM4E | |
| SCHEMBL3156543 | 0.76 | ALDH1A1 (1.00) | LMNAALDH1A1HRH3HRH4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | GLAXOSMITH KLINE LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | SIERRA ONCOLOGY, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2021-10-07 | — | — | US | disclosed |
| EP-3023422-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BioSciences Australia Pty Ltd (AU) | 2016-05-25 | — | — | EP | disclosed |
| US-9238628-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM Biosicences Australia PTY LTD (US) | 2016-01-19 | — | — | US | disclosed |
| US-9233934-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2152701-B1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2015-11-11 | — | — | EP | disclosed |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-02 | — | — | US | disclosed |
| US-8486941-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-07-16 | — | — | US | disclosed |
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2010-08-05 | — | — | US | disclosed |
| US-6545035-B1 | Having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-08 | — | — | US | disclosed |
| US-6319918-B1 | FOR LYMPHOMA OR SOLID TUMORS TREATMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | LMNA 4718/4885ALDH1A1 2269/4885MEN1 4037/4885 |
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | JAK1, JAK2, JAK3 | LMNA 4665/4885ALDH1A1 4184/4885MEN1 4629/4885 |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | LMNA 4718/4885ALDH1A1 2269/4885MEN1 4037/4885 |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | LMNA 4718/4885ALDH1A1 2269/4885MEN1 4037/4885 |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | JAK2, JAK1, JAK3 | LMNA 4718/4885ALDH1A1 2269/4885MEN1 4037/4885 |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | LMNA 4718/4885ALDH1A1 2269/4885MEN1 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.